ADMA Biologics Inc. is a biopharmaceutical company that is focused on the development and commercialization of specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The company's mission is to improve the health and quality of life of patients through the development of innovative and effective biologics.
ADMA was founded in 2004 and is headquartered in Ramsey, New Jersey. The company has a strong focus on research and development (R&D), with a team of scientists and researchers dedicated to developing new treatments for immune deficiencies and infectious diseases.
One of ADMA's key products is BIVIGAM, a polyvalent immunoglobulin (IgG) product that is used to treat patients with primary humoral immunodeficiency (PI). PI is a rare genetic disorder that is characterized by a defect in the immune system, which leads to recurrent infections and other health problems. BIVIGAM is designed to provide patients with the antibodies they need to fight off infections and improve their quality of life.
ADMA is also developing a number of other products for the treatment of immune deficiencies and infectious diseases. These include RI-002, a polyclonal antibody product that is designed to treat patients with respiratory syncytial virus (RSV) infections, and Asceniv, a human plasma-derived polyclonal antibody product that is designed to treat patients with primary humoral immunodeficiency (PI).
One of ADMA's key strengths is its focus on quality and regulatory compliance. The company has implemented a number of quality control and assurance measures to ensure that its products meet the highest standards of safety and efficacy. ADMA's manufacturing facility has been inspected and approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory agencies around the world.
Another strength of ADMA is its commitment to innovation and R&D. The company has a number of ongoing R&D programs focused on developing new treatments for immune deficiencies and infectious diseases. These programs are supported by a team of experienced scientists and researchers who are dedicated to advancing the field of biologics.
ADMA Biologics Inc. is a company that is committed to improving the health and quality of life of patients through the development of innovative and effective biologics. With a focus on quality, regulatory compliance, and innovation, ADMA is well-positioned to continue its success in the biopharmaceutical industry and make a positive impact on the world.
Comments